Drug recall · March 3, 2021
Irinotecan Hydrochloride Injection recall
Why: CGMP Deviations: based on a Warning Letter received by the manufacturer of the recalled product for inadequate out-of specification investigations, complaint and the investigation conclusions.
Class II: could cause temporary or reversible health problems; serious harm is remote.
The recall
- Product
Irinotecan Hydrochloride Injection, USP, 40 mg/2 mL (20 mg/mL), 2 mL Single-Dose Vial, Rx Only, Distributed by: Areva Pharmaceuticals, Inc., Gerogetown, IN 47122, Made in India, NDC 59923-714-02.
- Lots / codes
Lot 7S10022A, Exp Jan-21
- Quantity
- 3287 vials
- Company
- Areva Pharmaceuticals Inc, Georgetown, IN
- Distribution
- Nationwide in the USA
- Initiated
- November 19, 2020 · Voluntary: Firm initiated
- Classified
- February 21, 2021
- Reported
- March 3, 2021
- Ended
- December 28, 2022
- How notified
- Letter
The drug: prices, other makers, shortages
If you have this product
- Check the lot number on your package against the lots above. Only those lots are recalled.
- Don't stop a prescription medicine on your own. Call your pharmacy - they can swap it for an unaffected lot or another maker.
- Felt unwell? Contact your doctor, and report it to FDA MedWatch (1-800-FDA-1088 or fda.gov/medwatch).
- Return or dispose of recalled product as the company or your pharmacy advises.
Questions about this recall
No comments yet. Questions, tips, what worked for you - start the conversation.
Watch Irinotecan
One email when the price moves, a recall or shortage is posted, or the label changes. Plus the monthly biggest-movers report. Unsubscribe in one click.